HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teunissen, J. J.M. Articles by Krenning, E. P. Search for Related Content PubMed PubMed Citation Articles by Teunissen, J. J.M. Articles by Krenning, E. P.

Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma

¹ Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
² Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

View larger version (35K): [in a new window]   FIGURE 1. Time course of serum Tg and TSH levels in patient 3, 4, and 5 treated with 177Lu-DOTATATE. Broken lines represent pretherapy levels.

View larger version (92K): [in a new window]   FIGURE 2. Images comparing pretherapy 111In-octreotide scintigraphy (A) and posttherapy 177Lu-DOTATATE scintigraphy at 24 h (B). Top row shows corresponding images of tumor sites in patient 1 with metastatic PTC. Bottom row shows corresponding images of patient 3 with HCTC.

View larger version (16K): [in a new window]   FIGURE 3. Ratios of 177Lu-DOTATATE and 111In-octreotide uptake in tumor sites. Uptake was expressed as percentage of administered dose. Note differences in uptake between patients with HCTC who responded with MRe and PR and those who did not respond with tumor shrinkage.